In the DOAC group, there were 15 patients who were receiving an inappropriate treatment with dabigatran (which is not approved for the treatment of patients with stage 4 CKD) or with full doses of Factor Xa inhibitors (which should not be used in subjects with stage 4 CKD). Here, F10 is linked to chronic kidney disease.